TrialThe Lancet. Respiratory medicine2022

Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial.

Rolando Ochoa-Azze et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.